ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?

Tyrosine kinase inhibitors (TKIs) have become the preferred first line therapy for those patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Given superior progression free survival (PFS) and overall survival (OS) when compared to earlier gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagasaka, Misako, Ou, Sai-hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976558/
https://www.ncbi.nlm.nih.gov/pubmed/35378922
http://dx.doi.org/10.2147/LCTT.S355503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8976558/
https://www.ncbi.nlm.nih.gov/pubmed/35378922
http://dx.doi.org/10.2147/LCTT.S355503

Ejemplares similares